faisal

https://www.digipharm.ch/

The health system still relies heavily on old traditional methods. Technology is growing very fast, and time is not too far away when technology will be used in all aspects of life. Without a doubt, the use of technology improves and enhances everything.

Digipharm seeks to improve existing health care systems with the help of modern technology. It aims to restructure existing health care systems using technology along with their industry knowledge.

Our vision

To pioneer the delivery of sustainable and value-based health services, the generation of innovative evidence and patient empowerment across the health care industry.

Problem

Barriers to innovative pricing and 'paying for performance

Healthcare systems are often required to make their own limited resources. Innovative pricing approaches have the ability to overcome the challenges faced by healthcare systems when assessing the funding of new drugs, to enable the implementation of 'flexible' pricing schemes to assess the price of treatment in relation to the benefits it delivers. Unfortunately, healthcare systems around the world lack the relevant infrastructure to track and implement innovative pricing agreements, and so reluctant to adopt such innovative policies. This results in novel pharmacological therapies being the burden on health systems and a barrier to reimbursement for manufacturers.

Limitations of conventional real world evidence

Real world evidence (RWE) is playing an increasingly influential role in informing decision making within the healthcare industry and is crucial to informing value-based healthcare. Yet the delay of RWE outputs, the expenses of data access and the current methods of data collection. The lack of easily accessible and comprehensive RWE currently prevents stakeholders in healthcare to evaluate the real time performance and value provided by therapy in real life clinical practice as part of a value-based healthcare delivery system.

Solutions

Reimburse

The Reimburse platform harnesses the benefits of automated 'smart contracts' and blockchain technology; facilitating the application of truly dynamic innovative pricing solutions between healthcare systems and manufacturers, in a secure and compliant fashion with minimal administrative burden. Use of the Reimburse platform will expedite integration, coordination and delivery of patient centric healthcare systems with a focus on improving patient outcomes while accelerating 'payment for value' mechanisms between payers and manufacturers using neutrally-enforceable agreements in peer to peer fashion.

Insights

The Insights platform will extract anonymised patient level data from the Reimburse platform and health information systems to the world's first 'live' RWE database. Insights will provide a progressive transformation towards value-based healthcare delivery systems. The development of a 'live' evidence repository will allow the integration of knowledge back into the delivery system in real time to facilitate decision making, drug development and health related research. Patients will be incentivised to contribute their health information to the platform and will gain access to health information that is currently unattainable.

https://youtu.be/75zWPNKx9Qk

About Digipharm

Digipharm wants to address some of the real issues facing the health care system today with the help of private and public blockchain technology. In the Digipharm ecosystem there will be two platforms.

compensation

The replacement will allow patients, health authorities and suppliers to reduce risk. It also improves patient outcomes through cost-based pricing. The replacement platform will consist of the use of intelligent contracts to provide real-time pricing, which will be based on the application of personalized, cost-effective real-time work between payers and producers / suppliers. With the help of the Reimburse platform, the administrative costs will be significantly reduced.

Insight

The data will be extracted from Reimburse, and then they will be generated into the repository. Understanding is basically the real proof of world peace (RWE).

aim

Reduce infrastructure constraints and automate the implementation of innovative pricing agreements based on cost on fully independent platforms; facilitate the replacement of personal health technologies based on productivity costs for the joint benefits of patients, payers, and producers.

Develop the world's first RWE platform. Include the use of real data (RWD), as it becomes available to inform about scientific research in health, decision making and encourage patients to provide their data.

Future projects

MyHealth

The MyHealth platform will allow healthcare providers and payers to receive detailed patient reports so they can provide incentives for patients. The data collected on the MyHealth platform will enable healthcare providers to differentiate patients with lower and higher risks so they can offer better services to those in higher risk categories.

Provide funds for future projects

One of the main goals for the future is to provide sufficient funds for research and development.

Offer original coins

Digipharm aims to raise funds for medical innovation on the Evolve platform through crowdfunding and Initial Coin Offerering. Digipharm hopes that the Evolve platform will prove to be a valuable addition to fundraising in the future.

Digipharm token, which is also abbreviated, such as DPH, will be sold to ICO. This DPH token will be used across platforms. Payers and producers also need to use this DPH token.

Token characteristic

The DPH points will be based on the ERC-20 blockchain platform and will be an intellectual contract. ICO total DPH shipments will be limited to 100 000 000. stock codes for DPH DPH token will be, and can be served up to 18 decimal places, which is a good choice, considering the fact that prices will increase to make small transactions will be easy. It will cost $ 1.00 for each DPH token.

Here's a summary of what we said :

DPH Supply : 100,000,000 Fixed (ERC-20)
Symbol : DPH
Decimal number : 18
Token Price : 1.00 USD

On sale token

Sales in advance : 15,000,000 DPH
Discounts for sale : 35%
Basic price : 1.00 USD
Presale length : 4 weeks
Main sales : 50.000.000 DPH

Week 1 : 25%
Week 2 : 15%
Week 3 : 10%
Week 4 : 1.00 USD

command

The Digipharm team is supported by some really talented brains. General Manager Ahmed Abdullah has previous experience in a truly amazing place, including International Healthcare Limited and Liverpool University. CTO, Girisha Fernando entered the market with experience in various places, such as Portfolio Management. The other team members are highly qualified and enthusiastic about working on this idea.

Conclusion

Health is one of the most important things that we set today. Because the current system used by the health ecosystem is not so reliable. I feel that the inclusion of a blockade in this space is a demand of time and vision that Digipharm brings the power of the blockade to the health care system pretty sure. I would love to see how they promote this project.

Our Team